Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Multicenter Phase III Clinical Study Comparing the Combination of Sullimumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma

NCT07488533 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07488533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07488533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Multicenter Phase III Clinical Study Comparing the Combination of Sullimumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2025
Completion date
December 31, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-clear cell renal cell carcinoma